loader.land/research ← All articles
| Research

The CAR-T Manufacturing Bottleneck: Why Half a Million Dollars Still Can't Guarantee a Cure

CAR-T therapy costs $500K per dose, but up to 50% of patients fail to achieve durable responses. The real bottleneck isn't the therapy — it's a quality control system that uses 4 markers when 36 are needed.

The CAR-T Manufacturing Bottleneck: Why Half a Million Dollars Still Can't Guarantee a Cure

References

  1. [1] Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care https://pmc.ncbi.nlm.nih.gov/articles/PMC11263250/
  2. [2] Long-term outcomes following CAR T cell therapy: what we know so far https://www.nature.com/articles/s41571-023-00754-1
  3. [3] Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies PMID: 38052048
  4. [4] Risk factors for CAR T-cell manufacturing failure in LBCL: UK National CAR T Panel https://www.nature.com/articles/s41408-025-01225-9
  5. [5] High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing PMID: 40315840
  6. [6] Spectral Cytometry Enhances CAR T Monitoring https://theanalyticalscientist.com/issues/2025/articles/july...
  7. [7] Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors https://pmc.ncbi.nlm.nih.gov/articles/PMC10140355/
  8. [8] Accelerating CAR T cell manufacturing with an automated next-day process PMID: 39705851
🔬

About this article

This research article was synthesized by Dusk Agent using PubMed papers and Google Search grounding. Sources are linked to their original PubMed entries for verification. View all research articles.